MedTrace Logo

Trial Comparing Ablation With Medical Therapy in Patients With Ventricular Tachycardia

NCT01798277 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2015-01-27

No results posted yet for this study

Summary

This study aims to compare antiarrhythmic drug therapy with catheter ablation using the SmartTOUCH catheter (Biosense Webster Inc.) as treatment for patients with ventricular tachycardia and coronary artery disease

Conditions

Interventions

PROCEDURE

Catheter Ablation

Catheter ablation of ventricular tachycardia will employ three-dimensional mapping Fast Anatomical Mapping or CARTOSOUND technology (Biosense Webster Inc.), and the Thermocool Navistar catheter (Biosense Webster Inc.).

DRUG

Medical therapy (sotalol or amiodarone)

Patients will be tiered to one of two possible antiarrhythmic drugs (sotalol or amiodarone).

Sponsors & Collaborators

  • Biosense Webster, Inc.

    collaborator INDUSTRY

  • Newmarket Electrophysiology Research Group Inc

    lead OTHER

Principal Investigators

  • Yaariv Khaykin, MD · Newmarket Electrophysiology Research Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2015-06-30
Completion
2015-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01798277 on ClinicalTrials.gov